Nahm Ryune Cho

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Sk Biopharmaceuticals Co., Ltd., Amicogen Co., Ltd., Amicogen, Inc.. Active years: 2008-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nahm Ryune Cho. Retrieved from https://idiyas.com/inventor/nahm-ryune-cho

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 87.5

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 7.6

ph-index = 1

Forward Citations = 11(Granted Patents)

Company Filing History:

5 out of 109

Sk Biopharmaceuticals Co., Ltd.

Years Active: 2008-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12037338 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2024-07-16),

2. 11046702 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2021-06-29),

3. 10100057 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2018-10-16),

4. 9745310 - Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same (2017-08-29),

5. 8828697 - [object Object] (2014-09-09),

6. 8501436 - Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester (2013-08-06),

7. 8232083 - [object Object] (2012-07-31),

8. 7405070 - Method for preparing (s)-indoline-2-carboxylic acid and (s)-indoline-2-carboxylic acid methyl ester using hydrolytic enzyme (2008-07-29),

Title: Nahm Ryune Cho: Innovator in Pharmaceutical Chemistry

Introduction

Nahm Ryune Cho is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of eight patents. His work focuses on developing compounds that can positively impact health and treat various disorders.

Latest Patents

Among his latest patents are the imidazopyrimidine and imidazotriazine derivatives, which include a pharmaceutical composition comprising these compounds. The disclosed compounds act as positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). This innovation is particularly useful in the prevention or treatment of disorders mediated by glutamate dysfunction and mGluR5.

Career Highlights

Nahm Ryune Cho has worked with notable companies in the pharmaceutical industry, including SK Biopharmaceuticals Co., Ltd. and Amicogen, Inc. His expertise in drug development and chemistry has positioned him as a key figure in advancing therapeutic solutions.

Collaborations

Some of his notable coworkers include Ju Young Lee and Chun Eung Park, who have collaborated with him on various projects in the pharmaceutical sector.

Conclusion

Nahm Ryune Cho's innovative work in pharmaceutical chemistry and his numerous patents highlight his significant contributions to the field. His research continues to pave the way for advancements in treatments for disorders related to glutamate dysfunction.

Profile summary based on public USPTO records.